Usefulness of Cell‐Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy

MLA

Masaru Muraoka, et al. “Usefulness of Cell‐Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy.” Hepatology Communications, vol. 5, no. 11, Nov. 2021, pp. 1927–38. EBSCOhost, https://doi.org/10.1002/hep4.1762.

APA

Masaru Muraoka, Shinya Maekawa, Ryo Katoh, Yasuyuki Komiyama, Natsuko Nakakuki, Hitomi Takada, Shuya Matsuda, Yuichiro Suzuki, Mitsuaki Sato, Akihisa Tatsumi, Mika Miura, Fumitake Amemiya, Hiroko Shindo, Shinichi Takano, Mitsuharu Fukasawa, Kozue Yamauchi, Tatsuya Yamaguchi, Yasuhiro Nakayama, Taisuke Inoue, & Nobuyuki Enomoto. (2021). Usefulness of Cell‐Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy. Hepatology Communications, 5(11), 1927–1938. https://doi.org/10.1002/hep4.1762

Chicago

Masaru Muraoka, Shinya Maekawa, Ryo Katoh, Yasuyuki Komiyama, Natsuko Nakakuki, Hitomi Takada, Shuya Matsuda, et al. 2021. “Usefulness of Cell‐Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy.” Hepatology Communications 5 (11): 1927–38. doi:10.1002/hep4.1762.